CEL-SCI has completed all the developing and regulatory requirements to begin enrollment of the study 1 mg pills . The purpose of this research is to determine Multikine as a first-line standard of caution therapy in treating recently diagnosed head and neck cancer sufferers. The trial is thought to be the largest head and neck malignancy study ever carried out and is called ‘IT-Issues’, an acronym for: Immunotherapy Multikine Anti Tumor Remedies. CEL-SCI’s partners Teva Pharmaceuticals and Orient Europharma will conduct parts of the Phase III research in Israel and Taiwan respectively. All study sites, including those in Israel and Taiwan, are beneath the control of CEL-SCI’s global Clinical Study Organization. The trial is definitely open label, randomized, managed and patients are prospectively stratified.